Horizon Space II holds $70.8M trust but faces cash shortfall, shareholders' deficit and deal risk

Horizon Space Acquisition II Corp. (NASDAQ: HSPTU)

Quick read: the SPAC holds a healthy Trust Account invested in government-backed short-term securities and generated meaningful interest income in 2025, but operating cash is nearly depleted, accretion of redemption value has pushed reported shareholders' equity into a deficit, and management warns of substantial doubt about going concern. A business combination with SL Bio Ltd. is agreed (May 9, 2025) - but execution and financing risks remain.

Key facts & figures

- Trust Account balance: $70,801,049 (June 30, 2025)

- Total assets: $70,917,131

- Cash on hand: $26,030 (June 30, 2025)

- Total current liabilities: $427,852 (includes $254,484 due to related party)

- Ordinary shares subject to possible redemption: 6,900,000 (redeemable value presented as temporary equity - $70,801,049)

- Formation & operating costs: $509,166 (3 months ended June 30, 2025); $762,645 (six months)

- Interest & dividend income from Trust: $730,448 (3 months); $1,456,519 (six months)

- Reported net income (before redemption accretion): $221,282 (3 months); $693,874 (six months)

- Net loss including accretion to redemption value: $(509,166) (3 months); $(762,645) (six months)

- Basic/diluted net income per redeemable share: $0.050 (3 months); $0.127 (six months)

- Basic/diluted net loss per non‑redeemable share: $(0.056) (3 months); $(0.084) (six months)

- Shareholders' (deficit) equity: $(311,770) (June 30, 2025)

- Working capital deficit: $(311,770)

- Subsequent event: Sponsor issued an unsecured promissory note for $300,000 (July 5, 2025) to provide working capital (convertible into private units at $10/unit)

What's happening inside the company

- The company is a blank‑check (SPAC) that has not commenced operating activities beyond organizing, raising IPO proceeds and pursuing an announced Business Combination with SL Bio Ltd. (agreement dated May 9, 2025).

- Primary asset is the Trust Account (IPO proceeds) invested in U.S. treasury/money market instruments; interest earnings flow to the company and are being recognized as non‑operating income.

- Management continues to incur professional and transaction costs related to completing the Business Combination; cash outside the Trust is nearly exhausted, so short‑term liquidity depends on sponsor loans/working capital notes and completing the transaction.

Positive aspects (income statement & corporate position)

- Interest/dividend income is meaningful: $1.456M YTD (six months) - demonstrates the Trust Account is generating non‑operating cash inflows.

- Large, secure Trust Account: $70.8M - provides asset backing for potential redemption and the intended transaction consideration.

- Business Combination agreement signed with SL Bio (biotech focus) - a clear path to deploy Trust proceeds and convert SPAC into an operating company / combined public entity.

- Sponsor support: subsequent $300k working capital note indicates sponsor willingness to fund short-term needs and potentially convert into equity units.

Negative aspects (income statement & financial risks)

- Accretion to redemption value (accounting remeasurement of redeemable public shares) of $1.456M YTD offsets reported interest income and results in a net loss when included - this accretion is treated as a deemed dividend and reduced retained earnings/additional paid‑in capital.

- Operating/formational costs are non‑trivial ($762k six months) while cash outside the Trust fell to $26k, creating immediate liquidity stress for day‑to‑day expenses.

- Shareholders' deficit of $(311,770) and working capital deficit is indicative of near‑term funding needs and accounting pressure from redemption accretion.

- Management states substantial doubt about going concern - if additional financing (working capital loans or completion of the Business Combination) does not occur, liquidation is possible by November 18, 2025 (unless extended).

Operational & execution risks to monitor

- Redemption demand at business combination could materially increase cash needs (public shareholders can redeem), reducing funds available to the combined company.

- Completion of the SL Bio transaction depends on approvals, financing, and timing; failure would risk liquidation and trust‑account distribution to public shareholders.

- Sponsor loans/working capital conversions may dilute post‑combination equity; terms allow conversion at $10/unit.

- Geopolitical and market conditions (e.g., cross‑border considerations given ties to China/Taiwan) could affect the target's operations or financing availability.

Bottom line

Horizon Space Acquisition II Corp. (NASDAQ: HSPTU) sits on a large, secure Trust Account producing solid interest income and has signed a business combination with SL Bio - but the company's operating cash is nearly gone, redemption accretion has produced a reported shareholders' deficit and management warns of substantial doubt about the SPAC's ability to continue without sponsor funding or successful closing of the deal. Key things to watch: redemption levels at shareholder vote, progress and financing of the SL Bio combination, and any further sponsor/third‑party working capital commitments.